Nikolova AP, et al. - In this cohort study including 52 consecutive patients with a confirmed diagnosis of heart failure with preserved ejection fraction (HFpEF) (mean [SD] age, 57 [15] years; 33 [63%] male), researchers assessed the ability of a cardiac bridging integrator 1 (cBIN1, a marker of transverse tubule dysfunction)-derived score to be a diagnostic biomarker of HFpEF, compared to N-terminal pro-B-type natriuretic peptide (NT-proBNP). Using study participants in an ambulatory heart failure clinic at Cedars-Sinai Medical Center, the cBIN1 score (CS) was determined. Findings revealed that the cBIN1 score enabled a better differentiation of stable, ambulatory patients with HFpEF from age-matched and sex-matched healthy individuals and participants with heart failure risk factors but no HFpEF, when compared to NT-proBNP. Further validation of plasma CS may allow its use as a biomarker of cardiomyocyte remodeling that has the potential to aid in the diagnosis of HFpEF.